Literature DB >> 3277153

Five vs. ten days of therapy for acute otitis media.

W A Hendrickse1, H Kusmiesz, S Shelton, J D Nelson.   

Abstract

In a double blind study 175 patients with acute otitis media were randomized into 2 treatment groups: 10 days of therapy with cefaclor or 5 days of therapy followed by 5 days of placebo. The dosage of cefaclor was 40 mg/kg/day administered orally in equally divided doses at 12-hour intervals. Tympanocentesis before treatment yielded specimens that contained Streptococcus pneumoniae or Haemophilus influenzae or both in 55% of specimens. Branhamella catarrhalis was isolated from 21% of specimens. Culture of material from the ear canal of patients with spontaneous perforation of the tympanic membrane of less than 24 hours duration yielded pneumococci or H. influenzae or both in 38% of specimens and staphylococci in 31%. Patients were scheduled for follow-up examinations at 5 or 6, 10, 30, 60 and 90 days. Of the 175 children 151 were evaluable at 10 days. There were 123 patients with both tympanic membranes intact at the time of diagnosis. There were 6 (10%) treatment failures of therapy in the 59 patients assigned to 5 days of therapy and 4 (6%) failures and 1 (2%) early relapse in the 64 assigned to 10 days of therapy (difference not significant). There were 28 evaluable patients with spontaneous perforation. There were 8 (53%) failures in the 15 children assigned to 5 days of therapy and only 1 (8%) failure in the 13 children assigned to receive 10 days of therapy (P = 0.016, Fisher exact test). Rates of reinfection and persistent middle ear effusion at 10, 30, 60 and 90 days follow-up were not significant different in patients assigned to 5 to 10 days of therapy. In patients with acute otitis media with intact tympanic membranes we have not been able to show any advantage of the standard duration of 10 days of therapy over a shortened course of 5 days. A 5-day course of antibiotic therapy does not appear to be sufficient for children with acute otitis media and spontaneous purulent drainage.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3277153     DOI: 10.1097/00006454-198801000-00005

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  16 in total

1.  Do we need to treat otitis media?

Authors:  S Chaudhary
Journal:  Indian J Pediatr       Date:  1996 Jul-Aug       Impact factor: 1.967

2.  Management of acute otitis media.

Authors:  S Forgie; G Zhanel; J Robinson
Journal:  Paediatr Child Health       Date:  2009-09       Impact factor: 2.253

3.  Antibiotic management of acute otitis media.

Authors: 
Journal:  Paediatr Child Health       Date:  1998-07       Impact factor: 2.253

4.  Diagnosis and antibiotic treatment of acute otitis media: report from International Primary Care Network.

Authors:  J Froom; L Culpepper; P Grob; A Bartelds; P Bowers; C Bridges-Webb; I Grava-Gubins; L Green; J Lion; B Somaini
Journal:  BMJ       Date:  1990-03-03

Review 5.  Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.

Authors:  J A Balfour; P Benfield
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

6.  Five-day versus ten-day treatment of acute otitis media with cefprozil.

Authors:  D A Kafetzis; H Astra; L Mitropoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

Review 7.  Therapy of acute otitis media. Clinical and economic aspects.

Authors:  R Sagraves; W Maish
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

Review 8.  Principles of drug prescribing in infants and children. A practical guide.

Authors:  P D Walson; S Getschman; G Koren
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

9.  Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis.

Authors:  D Henry; G E Ruoff; J Rhudy; A Puopolo; M Drehobl; J Schoenberger; G Giguere; J J Collins
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

10.  Acute mastoiditis--relevant once again.

Authors:  J E Hoppe; S Köster; F Bootz; D Niethammer
Journal:  Infection       Date:  1994 May-Jun       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.